Modern technology gives us many things.

Canada intensifies vaccine campaign despite opposition

The first doses of Pfizer-BioNTech’s vaccine for children aged five to 11 arrived in Canada Sunday. More than 2.9 million doses are expected to be shipped by the end of the week. Such a move was adequate to provide a first dose to every eligible Canadian child. Earlier, Health Canada approved Pfizer-BioNTech’s vaccine for children aged five to 11. “After a thorough and independent scientific review of the evidence, the department has determined that the benefits of this vaccine for children between five and 11 years of age outweigh the risks,” Health Canada said in a news release. “This is the first COVID-19 vaccine authorized in Canada for use in this age group and marks a major milestone in Canada’s fight against COVID-19.” Health Canada said clinical trials showed the vaccine was 90.7 per cent effective at preventing COVID-19. No serious side effects were identified, it added.

Table of Contents

Boycott call

However, there is still some hesitancy and opposition for taking the vaccines in the country. Recently some anti-vaccine groups have called calling for a boycott of a family-run Canadian ice cream company. The groups said the company offered a pay rise to staff vaccinated against COVID-19. Rather than enforcing a hardline vaccine police, management at Chapman’s, Canada’s largest independent ice-cream manufacturer, gave a pay rise of $1 per hour for those who are vaccinated. However, some unvaccinated staff made a protest and sent the news to major Canadian anti-vaccine groups. They also issued a call to boycott the company online. It’s mandatory to get vaccinated in workplaces and public venues in the country from August. Meanwhile, the minister of public safety Marco Mendicino said any unvaccinated professional or amateur athletes will no longer be able to enter Canada from January 15. “As of January 15th, there will no longer be an exemption in place for professional and amateur athletes,” Mendocino said.

Comments are closed.